- Home
- MXCT
MXCT
MaxCyte Inc.
as 11-21-2024 11:36am EST
MaxCyte Inc is a commercial cell engineering company focused on providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics and to support cell-based research and development. The company has developed and commercialized a proprietary Flow Electroporation platform, which facilitates the complex engineering of a wide variety of cells. The revenue is generated from the sale and licensing of company's instruments, as well as sales of single-use disposable processing assemblies.
| Founded: | 1999 | Country: | United States |
| Employees: | N/A | City: | ROCKVILLE |
| Market Cap: | 398.3M | IPO Year: | 2021 |
| Target Price: | $8.67 | AVG Volume (30 days): | 588.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.21 - $5.55 | Next Earning Date: | 11-06-2024 |
| Revenue: | $45,599,000 | Revenue Growth: | 19.85% |
| Revenue Growth (this year): | -7.75% | Revenue Growth (next year): | 21.59% |
Stock Insider Trading Activity of MaxCyte Inc. (MXCT)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Johnston John Joseph | MXCT | Director | Oct 28 '24 | Sell | $3.72 | 3,000 | $11,166.00 | 141,950 | |
| Erck Stanley C | MXCT | Director | Oct 1 '24 | Sell | $3.75 | 47,689 | $178,751.93 | 269,118 | |
| Johnston John Joseph | MXCT | Director | Sep 26 '24 | Sell | $3.82 | 3,000 | $11,460.00 | 141,950 | |
| Erck Stanley C | MXCT | Director | Sep 3 '24 | Sell | $4.04 | 47,689 | $191,655.19 | 269,118 | |
| Johnston John Joseph | MXCT | Director | Aug 26 '24 | Sell | $4.28 | 3,000 | $12,840.00 | 141,950 |
Latest MaxCyte Inc. News
MXCT Breaking Stock News: Dive into MXCT Ticker-Specific Updates for Smart Investing
Simply Wall St.
11 hours ago
This MaxCyte Insider Increased Their Holding In The Last Year
GlobeNewswire
8 days ago
MaxCyte Celebrates 25 Years of Innovation Driving Cell Engineering-Based Therapeutics
GuruFocus.com
14 days ago
MaxCyte Inc (MXCT) Q3 2024 Earnings Call Highlights: Strong Core Revenue Growth Amidst Market ...
Zacks
15 days ago
MaxCyte, Inc. (MXCT) Reports Q3 Loss, Tops Revenue Estimates
GlobeNewswire
15 days ago
MaxCyte Reports Third Quarter 2024 Financial Results and Updates Full Year 2024 Guidance
GlobeNewswire
21 days ago
MaxCyte to Participate in Two Upcoming Investor Conferences
Simply Wall St.
22 days ago
MaxCyte, Inc. (LON:MXCT) is largely controlled by institutional shareholders who own 65% of the company
Zacks
a month ago
MaxCyte (MXCT) Upgraded to Strong Buy: What Does It Mean for the Stock?
Compare MXCT vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MXCT MaxCyte Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.